Top

Current Oncology Reports

Published in:

13-12-2023 | Breast Cancer

Exploring DESTINY: the Past, Present, and Future of Trastuzumab Deruxtecan

Authors: Azka Ali, Stephanie L. Graff

Published in: Current Oncology Reports | Issue 1/2024

Abstract

Purpose of Review

HER2-positive breast cancer accounts for 10–15% of all breast cancers and fam-trastuzumab deruxtecan (T-DXd) has played a major role in moving the treatment of HER2-expressing disease forward.

Recent Findings

T-DXd is a novel antibody–drug conjugate (ADC) composed of a humanized IgG1 monoclonal antibody against HER2 receptor bound to a potent topoisomerase I cytotoxin payload by a cleavable peptide linker. It has been shown to have robust preclinical activity in pretreated cancer cell lines, as well as meaningful clinical activity in advanced HER2-expressing breast cancer. Recent studies have demonstrated T-DXd as an active agent for metastatic HER2-positive patients, and as a viable additional line for heavily pretreated patients with HER2-low disease. The toxicity of T-DXd remains manageable and burden of side effects seems to be lower when offered as an earlier line of therapy over the course of treatment.

Summary

In this review, we discuss the pharmacology of T-DXd, review pertinent preclinical and clinical data, and address potential challenges and future directions related to the use of T-DXd in clinical practice.

Graff SL, Yan F, Abdou Y. Newly approved and emerging agents in HER2-positive metastatic breast cancer. Clin Breast Cancer. 2023. https://doi.org/10.1016/j.clbc.2023.05.003.CrossRefPubMed

Doi T, Shitara K, Naito Y, Shimomura A, Fujiwara Y, Yonemori K, et al. Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody-drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation study. The Lancet Oncology. 2017;18(11):1512–22. https://doi.org/10.1016/s1470-2045(17)30604-6.CrossRefPubMed

Okamoto H, Oitate M, Hagihara K, Shiozawa H, Furuta Y, Ogitani Y, et al. Pharmacokinetics of trastuzumab deruxtecan (T-DXd), a novel anti-HER2 antibody-drug conjugate, in HER2-positive tumour-bearing mice. Xenobiotica. 2020;50(10):1242–50. https://doi.org/10.1080/00498254.2020.1755909.CrossRefPubMed

Narayan P, Osgood CL, Singh H, Chiu HJ, Ricks TK, Chiu Yuen Chow E, et al. FDA approval summary: Fam-trastuzumab deruxtecan-Nxki for the treatment of unresectable or metastatic HER2-positive breast cancer. Clin Cancer Res. 2021;27(16):4478–85. https://doi.org/10.1158/1078-0432.Ccr-20-4557.CrossRefPubMedPubMedCentral

Su Z, Xiao D, Xie F, Liu L, Wang Y, Fan S, et al. Antibody-drug conjugates: Recent advances in linker chemistry. Acta Pharm Sin B. 2021;11(12):3889–907. https://doi.org/10.1016/j.apsb.2021.03.042.CrossRefPubMedPubMedCentral

Ogitani Y, Aida T, Hagihara K, Yamaguchi J, Ishii C, Harada N, et al. DS-8201a, A novel HER2-targeting ADC with a novel DNA topoisomerase I inhibitor, demonstrates a promising antitumor efficacy with differentiation from T-DM1. Clin Cancer Res. 2016;22(20):5097–108. https://doi.org/10.1158/1078-0432.CCR-15-2822.CrossRefPubMed

Tamura K, Tsurutani J, Takahashi S, Iwata H, Krop IE, Redfern C, et al. Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study. Lancet Oncol. 2019;20(6):816–26. https://doi.org/10.1016/S1470-2045(19)30097-X.CrossRefPubMed

• Modi S, Saura C, Yamashita T, Park YH, Kim SB, Tamura K, et al. Trastuzumab deruxtecan in previously treated HER2-positive breast cancer. N Engl J Med. 2020;382(7):610–21. https://doi.org/10.1056/NEJMoa1914510. (Of importance: Landmark phase 2 DESTINY-Breast01 study which showed efficacy of T-DXd in previously treated HER2-positive patients. Patients had a median 6 prior lines of therapy and ORR was 60.9%.)CrossRefPubMed

• André F, Hee Park Y, Kim SB, Takano T, Im SA, Borges G, et al. Trastuzumab deruxtecan versus treatment of physician’s choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial. Lancet. 2023. https://doi.org/10.1016/S0140-6736(23)00725-0. (Of outstanding importance: First phase 3 randomized T-DXd vs physician's choice of therapy study (DESTINY-Breast02). PFS was improved with T-DXd 17.8 months compared to 6.9 months in the control arm.)CrossRefPubMed

10.

• Cortés J, Kim SB, Chung WP, Im SA, Park YH, Hegg R, et al. Trastuzumab deruxtecan versus trastuzumab emtansine for breast cancer. N Engl J Med. 2022;386(12):1143–54. https://doi.org/10.1056/NEJMoa2115022. (Of outstanding importance: First T-DXd vs. T-DM1 head to head comparison study (DESTINY-Breast03) which showed superior PFS and ORR with T-DXd and established the role of T-DXd in the second line for HER2-positive metastatic patients.)CrossRefPubMed

11.

Hurvitz SA, Hegg R, Chung WP, Im SA, Jacot W, Ganju V, et al. Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial. Lancet. 2023;401(10371):105–17. https://doi.org/10.1016/s0140-6736(22)02420-5.CrossRefPubMed

12.

Curigliano G, Dunton K, Rosenlund M, Janek M, Cathcart J, Liu Y, et al. Patient-reported outcomes and hospitalization data in patients with HER2-positive metastatic breast cancer receiving trastuzumab deruxtecan or trastuzumab emtansine in the phase III DESTINY-Breast03 study. Ann Oncol. 2023;34(7):569–77. https://doi.org/10.1016/j.annonc.2023.04.516.CrossRefPubMed

13.

Enhertu (fam-trastuzumab deruxtecan-nxki) [package insert]. Wilmington, DE: AstraZeneca Pharmaceuticals; 2021. Accessed 10.17.2023.

14.

Manich CS, Modi S, Krop I, Park Y, Kim S, Tamura K, et al. 279P trastuzumab deruxtecan (T-DXd) in patients with HER2-positive metastatic breast cancer (MBC): updated survival results from a phase II trial (DESTINY-Breast01). Ann Oncol. 2021;32:S485–6.CrossRef

15.

Hamilton E, Shapiro C, Boni V, Jimenez MM, Del Conte G, Cortés J, et al. 162O Primary analysis from DS8201-A-U105: A 2-part, open label, phase Ib trial assessing trastuzumab deruxtecan (T-DXd) with nivolumab (nivo) in patients (pts) with HER2-expressing advanced breast cancer. Ann Oncol. 2022;33:S196.CrossRef

16.

• Modi S, Jacot W, Yamashita T, Sohn J, Vidal M, Tokunaga E, et al. Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer. N Engl J Med. 2022;387(1):9–20. https://doi.org/10.1056/NEJMoa2203690. (Of outstanding importance: Landmark phase 3 study (DESTINY-Breast04) comparing T-DXd with physician's choice of chemotherapy in previously treated metastatic HER2-low patients. Both PFS and OS were significantly approved. T-DXd has been since FDA approved for HER2-low patients.)CrossRefPubMedPubMedCentral

17.

Mosele F, Deluche E, Lusque A, Le Bescond L, Filleron T, Pradat Y, et al. Trastuzumab deruxtecan in metastatic breast cancer with variable HER2 expression: the phase 2 DAISY trial. Nat Med. 2023;29(8):2110–20. https://doi.org/10.1038/s41591-023-02478-2.CrossRefPubMedPubMedCentral

18.

Wolff AC, Hammond MEH, Allison KH, Harvey BE, Mangu PB, Bartlett JMS, et al. Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update. Arch Pathol Lab Med. 2018;142(11):1364–82. https://doi.org/10.5858/arpa.2018-0902-SA.CrossRefPubMed

19.

Tarantino P, Hamilton E, Tolaney SM, Cortes J, Morganti S, Ferraro E, et al. HER2-Low Breast Cancer: Pathological and Clinical Landscape. J Clin Oncol. 2020;38(17):1951–62. https://doi.org/10.1200/jco.19.02488.CrossRefPubMed

20.

Fehrenbacher L, Cecchini RS, Geyer CE, Rastogi P, Costantino JP, Atkins JN, et al. NSABP B-47/NRG oncology phase III randomized trial comparing adjuvant chemotherapy with or without trastuzumab in high-risk invasive breast cancer negative for HER2 by FISH and with IHC 1+ or 2. J Clin Oncol. 2020;38(5):444–53. https://doi.org/10.1200/JCO.19.01455.CrossRefPubMed

21.

Burris HA, Rugo HS, Vukelja SJ, Vogel CL, Borson RA, Limentani S, et al. Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy. J Clin Oncol. 2011;29(4):398–405. https://doi.org/10.1200/JCO.2010.29.5865.CrossRefPubMed

22.

Schmid P, Wysocki P, Park YH, Jassem J, Jung KH, Lord S, et al. Abstract PD11–08: PD11–08 Trastuzumab deruxtecan (T-DXd) + durvalumab (D) as first-line (1L) treatment for unresectable locally advanced/metastatic hormone receptor-negative (HR−), HER2-low breast cancer: updated results from BEGONIA, a phase 1b/2 study. Cancer Res. 2023;83((5_Supplement)):PD11-08-PD11-08. https://doi.org/10.1158/1538-7445.Sabcs22-pd11-08.CrossRef

23.

Desmoulins I, Bellio H, Méjean N, Truntzer C, Ladoire S. Intracranial response of brain metastases in patients with HER2-amplified breast cancer treated with trastuzumab-deruxtecan after failure of tucatinib-based therapy. Eur J Cancer. 2023;187:161–3. https://doi.org/10.1016/j.ejca.2023.03.030.CrossRefPubMed

24.

Jerusalem G, Park YH, Yamashita T, Hurvitz SA, Modi S, Andre F, et al. Trastuzumab deruxtecan in HER2-positive metastatic breast cancer patients with brain metastases: a DESTINY-Breast01 subgroup analysis. Cancer Discov. 2022;12(12):2754–62. https://doi.org/10.1158/2159-8290.Cd-22-0837.CrossRefPubMedPubMedCentral

25.

Kabraji S, Ni J, Sammons S, Li T, Van Swearingen AED, Wang Y, et al. Preclinical and clinical efficacy of trastuzumab deruxtecan in breast cancer brain metastases. Clin Cancer Res. 2023;29(1):174–82. https://doi.org/10.1158/1078-0432.CCR-22-1138.CrossRefPubMed

26.

Bartsch R, Berghoff AS, Furtner J, Marhold M, Bergen ES, Roider-Schur S, et al. Trastuzumab deruxtecan in HER2-positive breast cancer with brain metastases: a single-arm, phase 2 trial. Nat Med. 2022;28(9):1840–7. https://doi.org/10.1038/s41591-022-01935-8.CrossRefPubMedPubMedCentral

27.

Pérez-García JM, Vaz Batista M, Cortez P, Ruiz-Borrego M, Cejalvo JM, de la Haba-Rodriguez J, et al. Trastuzumab deruxtecan in patients with central nervous system involvement from HER2-positive breast cancer: The DEBBRAH trial. Neuro Oncol. 2023;25(1):157–66. https://doi.org/10.1093/neuonc/noac144.CrossRefPubMed

28.

Schlam I, Tolaney SM, Tarantino P. How I treat HER2-low advanced breast cancer. Breast. 2023;67:116–23. https://doi.org/10.1016/j.breast.2023.01.005.CrossRefPubMedPubMedCentral

29.

Hesketh PJ, Kris MG, Basch E, Bohlke K, Barbour SY, Clark-Snow RA, et al. Antiemetics: ASCO Guideline Update. J Clin Oncol. 2020;38(24):2782–97. https://doi.org/10.1200/jco.20.01296.CrossRefPubMed

30.

NCCN Clinical Practice Guidelines in Oncology Antiemesis.: https://www.nccn.org/professionals/physician_gls/pdf/antiemesis.pdf. Accessed 10.17.2023.

31.

Kumagai K, Aida T, Tsuchiya Y, Kishino Y, Kai K, Mori K. Interstitial pneumonitis related to trastuzumab deruxtecan, a human epidermal growth factor receptor 2-targeting Ab-drug conjugate, in monkeys. Cancer Sci. 2020;111(12):4636–45. https://doi.org/10.1111/cas.14686.CrossRefPubMedPubMedCentral

32.

Rugo HS, Crossno CL, Gesthalter YB, Kelley K, Moore HB, Rimawi MF, et al. Real-world perspectives and practices for pneumonitis/interstitial lung disease associated with trastuzumab deruxtecan use in human epidermal growth factor receptor 2-expressing metastatic breast cancer. JCO Oncol Pract. 2023;19(8):539–46. https://doi.org/10.1200/op.22.00480.CrossRefPubMedPubMedCentral

33.

Rugo H, Jacot W, Tokunaga E, Sohn J, Cardoso F, Xu B, et al. 185O Trastuzumab deruxtecan (T-DXd) vs treatment of physician’s choice (TPC) in patients (pts) with HER2-low unresectable and/or metastatic breast cancer (mBC): A detailed safety analysis of the randomized, phase III DESTINY-Breast04 trial. ESMO Open. 2023;8:1.CrossRef

34.

Tarantino P, Tolaney SM. Detecting and managing T-DXd-related interstitial lung disease: the five “S” rules. JCO Oncol Pract. 2023;19(8):526–7. https://doi.org/10.1200/op.23.00097.CrossRefPubMed

35.

Dent SF, Morse A, Burnette S, Guha A, Moore H. Cardiovascular toxicity of novel HER2-targeted therapies in the treatment of breast cancer. Curr Oncol Rep. 2021;23(11):128. https://doi.org/10.1007/s11912-021-01114-x.CrossRefPubMedPubMedCentral

36.

Rugo HS, Bianchini G, Cortes J, Henning JW, Untch M. Optimizing treatment management of trastuzumab deruxtecan in clinical practice of breast cancer. ESMO Open. 2022;7(4):100553. https://doi.org/10.1016/j.esmoop.2022.100553.CrossRefPubMedPubMedCentral

37.

National Comprehensive Cancer Network: https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf (Breast Cancer Version 4.2023). Accessed July 10, 2023.

38.

Diéras V, Deluche E, Lusque A, Pistilli B, Bachelot T, Pierga J-Y, et al. Abstract PD8–02: Trastuzumab deruxtecan (T-DXd) for advanced breast cancer patients (ABC), regardless HER2 status: a phase II study with biomarkers analysis (DAISY). Cancer Res. 2022;82((4_Supplement)):PD8-02--PD8.CrossRef

39.

Mosele M, Lusque A, Dieras V, Deluche E, Ducoulombier A, Pistilli B, et al. LBA1 Unraveling the mechanism of action and resistance to trastuzumab deruxtecan (T-DXd): Biomarker analyses from patients from DAISY trial. Ann Oncol. 2022;33:S123.CrossRef

40.

Guidi L, Pellizzari G, Tarantino P, Valenza C, Curigliano G. Resistance to antibody-drug conjugates targeting HER2 in breast cancer: molecular landscape and future challenges. Cancers (Basel). 2023;15:4. https://doi.org/10.3390/cancers15041130.CrossRef

41.

Abelman RO, Spring L, Fell GG, Ryan P, Vidula N, Medford AJ, et al. Sequential use of antibody-drug conjugate after antibody-drug conjugate for patients with metastatic breast cancer: ADC after ADC (A3) study. J Clin Oncol. 2023;41(16_suppl):1022. https://doi.org/10.1200/JCO.2023.41.16_suppl.1022.CrossRef

Title: Exploring DESTINY: the Past, Present, and Future of Trastuzumab Deruxtecan
Authors: Azka Ali
Stephanie L. Graff
Publication date: 13-12-2023
Publisher: Springer US
Keywords: Breast Cancer
Breast Cancer
Trastuzumab Deruxtecan
Published in: Current Oncology Reports / Issue 1/2024
Print ISSN: 1523-3790
Electronic ISSN: 1534-6269
DOI: https://doi.org/10.1007/s11912-023-01478-2

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose of Review

Recent Findings

Summary

Please log in to get access to this content

Other articles of this Issue 1/2024

Surgery for Recurrent Epithelial Ovarian Cancer

Immunotherapy for Early-Stage Triple Negative Breast Cancer: Is Earlier Better?

Measured Steps: Navigating the Path of Oligoprogressive Lung Cancer with Targeted and Immunotherapies

Male Breast Cancer: a Review on Diagnosis, Treatment, and Survivorship

Assessing Frailty in Gastrointestinal Cancer: Two Diseases in One?

Racial Disparities in Breast Cancer: from Detection to Treatment

Keynote webinar | Spotlight on antibody–drug conjugates in cancer